Key CHWs’ performance indicators by focus and time period. by Nicole Michelén Ströfer (19269154)

Training steps of the improved YOLOv4-Tiny. by Fuxing He (19555871)

“…Meanwhile, the improved model achieves a processing efficiency of 85 frames/s. In addition, compared with the traditional trajectory prediction model, the constructed model performs the best in table tennis ball trajectory prediction, with errors of 4.5 mm, 25.3 mm, and 35.58 mm. …”

Flowchart of SPM-GRU model operation. by Fuxing He (19555871)

“…Meanwhile, the improved model achieves a processing efficiency of 85 frames/s. In addition, compared with the traditional trajectory prediction model, the constructed model performs the best in table tennis ball trajectory prediction, with errors of 4.5 mm, 25.3 mm, and 35.58 mm. …”

NMP and PLU inhibit efflux activity in <i>Mycobacterium abscessus</i>. by Timilehin Faboro (20175963)

Loss variation curves of three models. by Fuxing He (19555871)

“…Meanwhile, the improved model achieves a processing efficiency of 85 frames/s. In addition, compared with the traditional trajectory prediction model, the constructed model performs the best in table tennis ball trajectory prediction, with errors of 4.5 mm, 25.3 mm, and 35.58 mm. …”

Overview of the composition of VSMC subpopulations in healthy mouse aorta. by Ya-Kun Gao (12280161)

<i>Shroom3</i> is expressed throughout the mouse myocardium during cardiogenesis. by Jennifer L. Carleton (22208916)

Fig 4 - by Ama tul Zahra (17941364)

4-OI enhances the clearance of MABC by THP-1 cells. by Paul Breen (5211830)

Fig 8 - by Ama tul Zahra (17941364)

<i>Shroom3</i> is expressed in the postnatal mouse heart. by Jennifer L. Carleton (22208916)

Fig 7 - by Ama tul Zahra (17941364)

Embryonic <i>Shroom3</i>^{<i>Gt</i>/<i>Gt</i>} hearts show abnormal semilunar valves. by Jennifer L. Carleton (22208916)

Adjustment for the individual conus medullaris (CM) length (60, 50, 40, and 30 mm for the displayed cases). by Silvan Büeler (18389510)

Myocardial <i>Shroom3</i> loss during development does not show abnormal semilunar valves. by Jennifer L. Carleton (22208916)

Myocardial <i>Shroom3</i> loss during development does not show ventricular septal defects. by Jennifer L. Carleton (22208916)

ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alo... by Rafael de Montier P. Barroso (10366820)

Participant demographics and characteristics. by Supattra Rungmaitree (12563948)

“…The factors associated with taking ≥6 pills/week were being MSM (adjusted odds ratio [aOR]: 53.2, 95% CI: 1.6–1811; <i>p</i> = 0.027), presence of STI at baseline (aOR: 9.4, 95% CI: 1.5–58.5; <i>p</i> = 0.016), and self-report of decreased condom use while taking PrEP (aOR: 8.7, 95% CI: 1.4–56.6; <i>p</i> = 0.023). 31% had an STI at baseline and this declined to 18% at week 24. …”

Study profile. by Supattra Rungmaitree (12563948)

“…The factors associated with taking ≥6 pills/week were being MSM (adjusted odds ratio [aOR]: 53.2, 95% CI: 1.6–1811; <i>p</i> = 0.027), presence of STI at baseline (aOR: 9.4, 95% CI: 1.5–58.5; <i>p</i> = 0.016), and self-report of decreased condom use while taking PrEP (aOR: 8.7, 95% CI: 1.4–56.6; <i>p</i> = 0.023). 31% had an STI at baseline and this declined to 18% at week 24. …”

Embryonic <i>Shroom3</i>^{<i>Gt</i>/<i>Gt</i>} hearts show left ventricular thinning. by Jennifer L. Carleton (22208916)